3B Blackbio
BSE: 3BBLACKBIO · Healthcare Service Provider
Snapshot
Unlock 3B Blackbio's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
3B Blackbio Dx Limited is a molecular diagnostics company that develops and manufactures qPCR, lateral flow, and Next Gen Sequencing kits for infectious diseases, oncology, and human genetics. The company also provides technical support, training services, and agrochemical products.
Business Model
The company generates revenue through the sale of proprietary molecular diagnostic kits under the TRUPCR, TRUNGS, and TRURAPID brands to diagnostic laboratories. It further monetises its expertise through technical training and the distribution of agrochemical products.
Growth Outlook
Growth is driven by the increasing demand for molecular diagnostics in infectious disease management and oncology. Continued innovation in Next Gen Sequencing and expansion of the diagnostic product portfolio remain key focus areas.
Key Risks
- Regulatory Risk. The company is subject to stringent regulatory approvals for its diagnostic kits, and any failure to comply with health authority standards could disrupt operations.
- Technological Obsolescence. The molecular diagnostics sector is highly competitive and subject to rapid technological advancements, requiring constant R&D investment to remain relevant.
- Market Competition. Intense competition from both domestic and international diagnostic players may exert pressure on pricing and market share.
- Supply Chain Dependency. Reliance on specialised raw materials and components for diagnostic kits makes the company vulnerable to global supply chain disruptions.
Price
Start your research today
Unlock AI insights, financials, peers and live data on 3B Blackbio and 5,000+ companies — free.
Key Metrics
REVENUE
₹142 Cr
TTM · consolidated
NET PROFIT
₹60 Cr
TTM · consolidated
EPS
₹69.94
TTM · consolidated
RETURN ON EQUITY
21.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
26.3%
TTM · consolidated
P/E
18.1x
Q4 FY26 · consolidated
EV/EBITDA
12.7x
Q4 FY26 · consolidated
EBITDA MARGIN
58.0%
TTM · consolidated
NET PROFIT MARGIN
27.7%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Healthcare Service Provider
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
3B Blackbio3BBLACKBIO | 1,064 | 18.14 | 12.67 | 41.9% | 58.0% | 21.2% | 26.3% | -19.9% |
Thyrocare Technologies Ltd.THYROCARE | 5,857 | 24.86 | 9.89 | 20.6% | 33.7% | 29.3% | 36.5% | -56.0% |
Nephrocare Health ServicesNEPHROPLUS | 5,259 | — | — | — | 22.0% | — | — | — |
Krsnaa Diagnostics Ltd.KRSNAA | 1,832 | 17.47 | 8.92 | 7.8% | 33.0% | 11.2% | 14.7% | -34.5% |
Suraksha Diagnostic Ltd.SURAKSHA | 1,318 | 41.25 | 13.66 | — | 32.1% | 14.7% | 18.4% | -19.9% |
Gaudium IVFGAUDIUMIVF | 569 | — | — | — | 36.0% | — | — | — |
As of Q4 FY26
Financials
3B Blackbio
BSE: 3BBLACKBIO · Healthcare Service Provider
Snapshot
Unlock 3B Blackbio's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
3B Blackbio Dx Limited is a molecular diagnostics company that develops and manufactures qPCR, lateral flow, and Next Gen Sequencing kits for infectious diseases, oncology, and human genetics. The company also provides technical support, training services, and agrochemical products.
Business Model
The company generates revenue through the sale of proprietary molecular diagnostic kits under the TRUPCR, TRUNGS, and TRURAPID brands to diagnostic laboratories. It further monetises its expertise through technical training and the distribution of agrochemical products.
Growth Outlook
Growth is driven by the increasing demand for molecular diagnostics in infectious disease management and oncology. Continued innovation in Next Gen Sequencing and expansion of the diagnostic product portfolio remain key focus areas.
Key Risks
- Regulatory Risk. The company is subject to stringent regulatory approvals for its diagnostic kits, and any failure to comply with health authority standards could disrupt operations.
- Technological Obsolescence. The molecular diagnostics sector is highly competitive and subject to rapid technological advancements, requiring constant R&D investment to remain relevant.
- Market Competition. Intense competition from both domestic and international diagnostic players may exert pressure on pricing and market share.
- Supply Chain Dependency. Reliance on specialised raw materials and components for diagnostic kits makes the company vulnerable to global supply chain disruptions.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on 3B Blackbio and 5,000+ companies — free.
Key Metrics
REVENUE
₹142 Cr
TTM · consolidated
NET PROFIT
₹60 Cr
TTM · consolidated
EPS
₹69.94
TTM · consolidated
RETURN ON EQUITY
21.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
26.3%
TTM · consolidated
P/E
18.1x
Q4 FY26 · consolidated
EV/EBITDA
12.7x
Q4 FY26 · consolidated
EBITDA MARGIN
58.0%
TTM · consolidated
NET PROFIT MARGIN
27.7%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Healthcare Service Provider
As of Q4 FY26